CAS: 1402608-02-9

BAY1125976 is an allosteric inhibitor of Akt1 and Akt2 (IC50s of 5.2 and 18 nM, respectively, in a time-resolved FRET assay)

BAY1125976 is a potent and selective CDK4/6 inhibitor. It binds to the ATP-binding site on these kinases, which are necessary for cell division. BAY1125976 has been shown to have an inhibitory effect on cancer cells in vitro and in vivo. It significantly reduces tumor growth without causing any adverse effects in the healthy cells. The primary mechanism of action is thought to be through inhibition of protein synthesis, which leads to reduced cell proliferation and decreased tumor growth. Bay 112596 is a potent and selective CDK4/6 inhibitor that binds to the ATP-binding site on these kinases, which are necessary for cell division. BAY 112596 has been shown to have an inhibitory effect on cancer cells in vitro and in vivo. It significantly reduces tumor growth without causing any adverse effects in the healthy cells. The primary mechanism of action is thought to be through inhibition of protein synthesis, which leads to reduced cell proliferation and decreased tumor growth

BAY1125976